A036220 Stock Overview
Researches, develops, and sells various diagnostic biosensors in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Osang Healthcare Co.,Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩15,530.00 |
52 Week High | ₩45,000.00 |
52 Week Low | ₩13,090.00 |
Beta | 10.58 |
11 Month Change | 0.13% |
3 Month Change | 2.85% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -54.94% |
Recent News & Updates
Recent updates
Shareholder Returns
A036220 | KR Medical Equipment | KR Market | |
---|---|---|---|
7D | -7.0% | -2.6% | -2.6% |
1Y | n/a | 18.2% | 2.2% |
Return vs Industry: Insufficient data to determine how A036220 performed against the KR Medical Equipment industry.
Return vs Market: Insufficient data to determine how A036220 performed against the KR Market.
Price Volatility
A036220 volatility | |
---|---|
A036220 Average Weekly Movement | 5.9% |
Medical Equipment Industry Average Movement | 5.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A036220 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A036220's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 325 | Man-Suk Ko | www.osanghc.com |
Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide.
Osang Healthcare Co.,Ltd Fundamentals Summary
A036220 fundamental statistics | |
---|---|
Market cap | ₩217.25b |
Earnings (TTM) | -₩3.25b |
Revenue (TTM) | ₩90.98b |
2.4x
P/S Ratio-66.9x
P/E RatioIs A036220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A036220 income statement (TTM) | |
---|---|
Revenue | ₩90.98b |
Cost of Revenue | ₩58.11b |
Gross Profit | ₩32.88b |
Other Expenses | ₩36.13b |
Earnings | -₩3.25b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -232.26 |
Gross Margin | 36.13% |
Net Profit Margin | -3.57% |
Debt/Equity Ratio | 0% |
How did A036220 perform over the long term?
See historical performance and comparison